Entering text into the input field will update the search result below

Ariad restructures license agreement with Bellicum

Oct. 06, 2014 9:30 AM ETARIAD Pharmaceuticals, Inc. (ARIA) StockBy: Douglas W. House, SA News Editor
  • Privately-held Bellicum Pharmaceuticals pays Ariad Pharmaceuticals (NASDAQ:ARIA) $50M for a full license to Ariad's cell-signalling technology. Under the terms of the revised agreement, Ariad will receive $15M upon the signing of the agreement, $20M by June 30, 2015 and $15M by June 30, 2016. Bellicum's license will be free of milestone and royalty payments.
  • Bellicum is developing controllable stem cell transplant, chimeric antigen receptor T cell and cancer vaccine product candidates for a variety of diseases.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
ARIA--
ARIAD Pharmaceuticals, Inc.